Frequently asked questions
CJC-1295: frequently asked questions, answered from the record
Direct, cited answers to the questions readers ask most — definitions, regulatory standing, the DAC distinction, safety signals, and research dosing.
Definitions and what it does
What is CJC-1295?
CJC-1295 is a long-acting synthetic analog of growth-hormone-releasing hormone built on hGRF(1-29) with four protease-resistant substitutions [2]. The DAC variant adds covalent serum-albumin conjugation for a multi-day half-life [2]. It stimulates the body's own growth hormone rather than supplying GH directly.
What does CJC-1295 do?
In studies it binds the pituitary GHRH receptor, stimulating pulsatile growth-hormone release and a downstream rise in IGF-1 [3]. In healthy adults, single doses raised GH and IGF-1 for days [1]. It amplifies the GH/IGF-1 axis rather than replacing it.
Is CJC-1295 a steroid?
No. CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH); it acts on the pituitary GHRH receptor to stimulate the body's own growth hormone, rather than acting as an anabolic-androgenic steroid [2]. Its target is the GH/IGF-1 axis, not the androgen receptor.
What is CJC-1295 ipamorelin?
A common research pairing of a GHRH analog (CJC-1295) with a selective GH secretagogue (ipamorelin); the two engage distinct pathways and synergize on GH release [11]. The pairing is a mechanistic rationale rather than a validated regimen, with limited controlled efficacy data in healthy adults.
Regulatory and anti-doping status
Is CJC-1295 FDA approved?
No. CJC-1295 is an unapproved research chemical with no approved human indication anywhere. It is not on the FDA 503A compounding bulks list; the 2024 Pharmacy Compounding Advisory Committee reviewed it and did not recommend it [13].
What did the 2024 FDA Pharmacy Compounding Advisory Committee say about CJC-1295?
FDA briefing materials for the 2024 PCAC reviewed GH secretagogues including CJC-1295 and cited immunogenicity and other safety concerns as part of the basis for not recommending it for the 503A compounding bulks list [13]. The committee did not recommend it for compounding eligibility.
What is CJC-1295's WADA status for tested athletes?
The World Anti-Doping Agency prohibits CJC-1295 at all times under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), in and out of competition [15]. Established LC-MS/MS and immuno-PCR assays detect it, and CJC-1295 has been structurally identified in seized preparations by high-resolution mass spectrometry [16].
Why does the FDA cite immunogenicity as a concern for CJC-1295?
Synthetic peptides can provoke anti-drug antibodies; the FDA's 2024 PCAC briefing flagged immunogenicity, alongside other safety concerns, for GH secretagogues including CJC-1295 when weighing 503A compounding eligibility [13]. Immunogenicity is a recognized risk class for synthetic peptide therapeutics generally.
DAC, no-DAC and the half-life
What is CJC-1295 with DAC?
The DAC ("Drug Affinity Complex") variant carries a maleimide linker that covalently binds circulating serum albumin, extending the plasma half-life toward that of albumin and giving a multi-day duration [2]. It is the long-acting form of the peptide.
What is CJC-1295 DAC?
CJC-1295 DAC is the albumin-conjugated, long-acting form; in rats it produced roughly 4-fold higher GH AUC than unconjugated peptide and remained detectable in plasma beyond 72 hours [2]. In healthy adults its estimated half-life was 5.8 to 8.1 days [1].
How much CJC-1295 DAC should I take?
Human PK work used 30-90 micrograms-per-kilogram single subcutaneous doses of the DAC form, which has a 5.8-to-8.1-day half-life, so it was studied on infrequent schedules [1][3]. No approved human dose exists for any indication.
How much CJC-1295 should I take?
Published human PK studies used single subcutaneous doses of 30, 60 or 90 micrograms per kilogram in research settings [1][3]. No human dosing is established for any indication; circulating fixed-dose protocols are not derived from controlled trials [7].
Handling, safety and effects
How to reconstitute CJC-1295?
In research handling, the lyophilized peptide is reconstituted with bacteriostatic water and refrigerated [1]. This is laboratory handling information, not a use instruction; CJC-1295 is not approved for human use anywhere.
Where to inject CJC-1295?
The route studied in the literature is subcutaneous injection [1]. This describes how the compound was administered in research; no human use is approved or recommended.
How much CJC-1295 / ipamorelin should I take?
There is no controlled human trial of the CJC-1295/ipamorelin pairing to derive a dose from; the rationale for combining them is mechanistic (distinct receptors), not a validated regimen [11]. Forum figures are not evidence.
Does CJC-1295 and ipamorelin work?
Mechanistically, GHRH analogs and GHRPs act on different receptors and co-administration produces GH release greater than either alone [11]; controlled efficacy data for this specific pairing in healthy adults are limited [11].
Is CJC-1295 safe?
There is no large human safety dataset. The long-acting DAC program was discontinued; sustained GH/IGF-1 elevation raises theoretical concerns (fluid retention, IGF-1/cancer epidemiology), and the FDA flagged immunogenicity [13][14]. It remains an unapproved research chemical [7].
Are CJC-1295 peptides safe?
Published human exposure is limited to early PK studies; there is no long-term safety dataset, the DAC clinical program was halted, and the FDA flagged immunogenicity [13][7]. CJC-1295 is an unapproved research chemical.
Does CJC affect testosterone?
CJC-1295 acts on the GH/IGF-1 axis, which is distinct from the gonadal (testosterone) axis [2]; published CJC-1295 studies measured GH and IGF-1, not androgens, and did not characterize it as a testosterone-altering agent [3].
What are the side effects of CJC-1295?
There is no controlled adverse-event dataset in healthy adults [7]. GH-axis stimulation can cause fluid retention and edema; theoretical concerns include effects on insulin sensitivity and IGF-1/cancer epidemiology, and the FDA cited immunogenicity [13][14].
What to expect when taking CJC-1295?
This is a research-context question, not a use recommendation. In human PK studies, single doses raised mean GH several-fold and IGF-1 by roughly 45%, with effects persisting for days; outcomes in uncontrolled settings are not established [3].
Does CJC-1295 lower testosterone?
No published CJC-1295 study reports it as a testosterone-lowering agent; its target is the GH/IGF-1 axis [2][3]. Claims that it raises or lowers testosterone are not supported by the peer-reviewed literature on the compound.